Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Autolus Therapeutics (AUTL) Other financing activities: 2021-2024

Historic Other financing activities for Autolus Therapeutics (AUTL) over the last 2 years, with Jun 2024 value amounting to $1.8 million.

  • Autolus Therapeutics' Other financing activities rose 740.18% to $1.8 million in Q2 2024 from the same period last year, while for Jun 2024 it was $30.3 million, marking a year-over-year increase of 168.54%. This contributed to the annual value of $29.4 million for FY2024, which is 3126.37% up from last year.
  • According to the latest figures from Q2 2024, Autolus Therapeutics' Other financing activities is $1.8 million, which was down 93.31% from $27.5 million recorded in Q1 2024.
  • Over the past 5 years, Autolus Therapeutics' Other financing activities peaked at $27.5 million during Q1 2024, and registered a low of -$7.6 million during Q1 2021.
  • Moreover, its 3-year median value for Other financing activities was $691,000 (2023), whereas its average is $5.8 million.
  • Per our database at Business Quant, Autolus Therapeutics' Other financing activities decreased by 9.67% in 2022 and then surged by 69,200.00% in 2023.
  • Over the past 4 years, Autolus Therapeutics' Other financing activities (Quarterly) stood at $11.5 million in 2021, then decreased by 9.67% to $10.3 million in 2022, then skyrocketed by 69,200.00% to $219,000 in 2023, then spiked by 740.18% to $1.8 million in 2024.
  • Its last three reported values are $1.8 million in Q2 2024, $27.5 million for Q1 2024, and $219,000 during Q2 2023.